Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma (vol 127, pg 2561, 2016)

被引：0
|
作者：
Baz, R. C.
Martin, T. G., III
Lin, H-Y
机构：
来源：
BLOOD | 2016年 / 128卷 / 03期
关键词：
D O I：
10.1182/blood-2016-06-721886
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：461 / 461
页数：1
相关论文
共 50 条
  • [31] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
    Rosenbaum, Cara Ann
    Stephens, Leonor Ano
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cole, Craig
    Zimmerman, Todd M.
    Reece, Donna Ellen
    Berdeja, Jesus G.
    Severson, Erica
    Revethis, Andrea
    Wolfe, Brittany
    McDonnell, Kathryn
    Nam, Jennifer
    Griffith, Kent A.
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma
    Sebag, Michael
    Bahlis, Nizar J.
    Venner, Christopher P.
    McCurdy, Arleigh
    Kouroukis, C. Tom
    Shustik, Jesse
    Kotb, Rami
    White, Darrell J.
    Stakiw, Julie
    Laferriere, Nicole B.
    Reiman, Anthony
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna E.
    BLOOD, 2020, 136
  • [33] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richardson, Paul
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Karanes, Chatchada
    Campana, Frank
    Kanagavel, Dheepak
    Dubin, Franck
    Liu, Qianying
    Semiond, Dorothee
    Anderson, Kenneth
    BLOOD, 2019, 134 (02) : 123 - 133
  • [34] A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma
    Sebag, Michael
    Bahlis, Nizar
    Venner, Christopher P.
    McCurdy, Arleigh
    Kouroukis, C. Tom
    Shustik, Jesse
    White, Darrell J.
    Kotb, Rami
    Stakiw, Julie
    Laferriere, Nicole B.
    Reiman, Tony
    Camacho, Fernando
    Dobbin, Julia
    Fu, Molei
    Gul, Engin
    Reece, Donna E.
    BLOOD, 2019, 134
  • [35] Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort
    Baz, Rachid
    Shain, Kenneth H.
    Alsina, Melissa
    Nardelli, Lisa A.
    Nishihori, Taiga
    Ochoa, Leonel
    Martin, Thomas
    Jagannath, Sundar
    Dalton, William
    Sullivan, Daniel M.
    BLOOD, 2012, 120 (21)
  • [36] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
  • [37] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)
    Niederwieser, Dietger
    Richardson, Paul
    Attal, Michel
    Rajkumar, Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulosu, Meletios
    Huan, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Mace, Sandrine
    Prince, H. Miles
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 40 - 41
  • [39] Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial
    Weisel, Katja C.
    Salwender, Hans Jurgen
    Scheid, Christof
    Zago, Manola
    Besemer, Britta
    Hanel, Mathias
    Durig, Jan
    Munder, Markus
    Lindemann, Hans-Walter
    Seckinger, Anja
    Kunz, Christina
    Benner, Axel
    Hose, Dirk
    Jauch, Anna
    Kanz, Lothar
    Goldschmidt, Hartmut
    BLOOD, 2017, 130
  • [40] Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
    Sonneveld, Pieter
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    Ukropec, Jon
    Smith, Elena
    Houkes, Nienke
    Schecter, Jordan Mark
    Kastritis, Efstathios
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345